Cingulate Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cingulate de 46.8% y 68.5% respectivamente, mientras que el BPA crecerá en un 77.8% al año.

Información clave

46.8%

Tasa de crecimiento de los beneficios

77.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	68.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Aug 26

Cingulate Q2 GAAP EPS of -$0.36

Aug 11

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Apr 04

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CING - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	4	-7	N/A	N/A	2
12/31/2025	N/A	-13	N/A	-14	3
12/31/2024	N/A	-13	N/A	-12	3
9/30/2024	N/A	-16	-17	-17	N/A
6/30/2024	N/A	-19	-18	-17	N/A
3/31/2024	N/A	-23	-20	-20	N/A
12/31/2023	N/A	-24	-15	-15	N/A
9/30/2023	N/A	-21	-17	-17	N/A
6/30/2023	N/A	-19	-16	-16	N/A
3/31/2023	N/A	-17	-16	-16	N/A
12/31/2022	N/A	-18	-16	-16	N/A
9/30/2022	N/A	-16	-17	-16	N/A
6/30/2022	N/A	-27	-16	-15	N/A
3/31/2022	N/A	-24	-13	-13	N/A
12/31/2021	N/A	-21	-11	-10	N/A
9/30/2021	N/A	-19	-8	-8	N/A
6/30/2021	N/A	-5	-7	-7	N/A
3/31/2021	N/A	-6	-7	-7	N/A
12/31/2020	N/A	-7	-7	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CING siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CING siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CING siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que CING no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que CING no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CING se prevé que sea elevada dentro de 3 años.

Cingulate Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

No longer forecast to breakeven

Recent updates

The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024

Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

Cingulate Inc., Annual General Meeting, Jun 11, 2024

Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer

Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million.

Cingulate Receives Non-Compliance Notice from Nasdaq

Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone)

Cingulate Inc. has filed a Follow-on Equity Offering.

The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel

Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations

Cingulate Weighs Reverse Stock Split to Avoid Delisting

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million.

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd

Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August

New major risk - Market cap size

Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd

Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

Cingulate Inc., Annual General Meeting, Jun 15, 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors

Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Independent Director recently bought US$75k worth of stock

Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Inc. Provides Clinical Update

Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors

Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Cingulate Inc. Appoints Scott Applebaum as Class III Director

Cingulate Q2 GAAP EPS of -$0.36

Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety

Cingulate Inc., Annual General Meeting, Jun 08, 2022

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$89k worth of stock

Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento